the future of MenACWY protection,


Because we believe one case is one too many

hero line

At Sanofi, we believe that our work in fighting meningococcal disease is never done. That’s why we’ve developed MenQuadfi, our latest innovation in MenACWY vaccination.1

MenQuadfi is a vaccine indicated for active immunization for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. MenQuadfi is approved for use in individuals 2 years of age and older. MenQuadfi does not prevent N meningitidis serogroup B disease.1

MenQuadfi is a solution that does not require reconstitution and will allow you to reimagine how you can help protect against meningococcal disease.1


head-to-head data

MenQuadfi has been evaluated in head-to-head clinical trials vs Menveo® and Menactra®.1,2*

NOVEL DESIGN beaker icon

Novel design

MenQuadfi was developed using a novel serogroup-specific approach.1


MenQuadfi should not be administered to anyone who has had a severe allergic reaction to any component of the vaccine, or after a previous dose of MenQuadfi or any other tetanus toxoid-containing vaccine.

Appropriate observation and medical treatment should always be readily available in case of an anaphylactic event following the administration of the vaccine.

Some individuals with altered immunocompetence, including some individuals receiving immunosuppressant therapy, may have reduced immune responses to MenQuadfi. Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (eg, eculizumab) are at increased risk for invasive disease caused by N meningitidis, including invasive disease caused by serogroups A, C, W, and Y, even if they develop antibodies following vaccination with MenQuadfi.

Syncope can occur following, or even before, vaccination with MenQuadfi. Procedures should be in place to prevent falling and injury and to manage syncope.

Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision to give MenQuadfi to persons with a history of GBS should take into account the expected benefits and potential risks.

Immunization with MenQuadfi does not substitute for routine tetanus immunization.

Vaccination with MenQuadfi may not protect all vaccine recipients.

The most common adverse reactions following a primary dose of MenQuadfi in individuals 2 years of age and older include pain at the injection site; myalgia, headache, and malaise. Other common adverse reactions in children 2 through 9 years of age include erythema and swelling at the injection site. In adolescents and adults, rates of solicited adverse reactions following a booster dose were comparable to those observed following primary vaccination. Other adverse reactions may occur.

Please see the full Prescribing Information for MenQuadfi.

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.

MenACWY = N meningitidis serogroups A, C, W, and Y. * Menveo (Meningococcal [Groups A, C, Y, and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine). Menactra (Meningococcal [Groups A, C, Y, and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine).

MenQuadfi is a registered trademark of Sanofi Pasteur Inc.

Menactra is a registered trademark of Sanofi, its affiliates, and its subsidiaries.

The other brands listed are trademarks owned by or licensed to their respective owners and are not owned by or licensed to Sanofi, its affiliates and/or its subsidiaries.


  1. MenQuadfi [Prescribing Information]. Sanofi Pasteur Inc.
  2. Sanofi Pasteur Inc. Data on File. July 27, 2020.
  3. Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69(9):1-41.

Back to the top

This site is intended for U.S. Healthcare Professionals Only.

MAT-US-2007152-v8.0-6/2024 Last Updated: 06/2024